Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICING: Bintrafusp Alfa in Pre-op HNSCC
NCT04428047Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by Unicancer. Started Feb 2021; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04428047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428047.